In order to improve the accuracy of HER2 testing in invasive breast cancer, the American Society of Clinical Oncology and the College of American Pathologists (ASCO/CAP) first drafted a guideline for HER2 testing in breast cancer in 2007 [10]. The gene discussed is ERBB2; the disease is breast cancer.